Research & Literature

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Kunkler IH, Williams LJ, Jack WJ, et al.

The Lancet. Oncology 2015; (16(3)):266-73.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, et al.

Lancet (London, England) 2015; (386(9992)):433-43.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Bernhard J, Luo W, Ribi K, et al.

The Lancet. Oncology 2015; (16(7)):848-58.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Lancet (London, England) 2015; (386(10001)):1353-1361 doi:10.1016/S0140-6736(15)60908-4.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Lancet (London, England) 2015; (386(10001)):1341-1352 doi:10.1016/S0140-6736(15)61074-1.

Clinical implications of the intrinsic molecular subtypes of breast cancer.

Prat A, Pineda E, Adamo B, et al.

Breast (Edinburgh, Scotland) 2015; (24 Suppl 2()):S26-35.

Current medical treatment of estrogen receptor-positive breast cancer.

Lumachi F, Santeufemia DA, Basso SM

World journal of biological chemistry 2015; (6(3)):231-9 doi:10.4331/wjbc.v6.i3.231.

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Yamashita H, Ogiya A, Shien T, et al.

Breast cancer (Tokyo, Japan) 2016; (23(6)):830-843 doi:10.1007/s12282-015-0649-0.

An Assessment of Margins after Lumpectomy in Breast Cancer Management.

Rivere AE, Chiasson KF, Corsetti RL, Fuhrman GM

The American surgeon 2016; (82(2)):156-60.

Interobserver Variability of Ki-67 Measurement in Breast Cancer.

Chung YR, Jang MH, Park SY, et al.

Journal of pathology and translational medicine 2016; (50(2)):129-37 doi:10.4132/jptm.2015.12.24.

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.

Rydén L, Heibert Arnlind M, Vitols S, et al.

Breast (Edinburgh, Scotland) 2016; (26()):106-14.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Regan MM, Francis PA, Pagani O, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2221-31 doi:10.1200/JCO.2015.64.3171.

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

Buus R, Sestak I, Kronenwett R, et al.

Journal of the National Cancer Institute 2016; (108(11)) doi:10.1093/jnci/djw149.

Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.

Arihiro K, Oda M, Ohara M, et al.

Japanese journal of clinical oncology 2016; (46(12)):1081-1087 doi:10.1093/jjco/hyw107.

Supportive care of women with breast cancer: key concerns and practical solutions.

Zdenkowski N, Tesson S, Lombard J, et al.

The Medical journal of Australia 2016; (205(10)):471-475 doi:10.5694/mja16.00947.

Palbociclib and Letrozole in Advanced Breast Cancer.

Finn RS, Martin M, Rugo HS, et al.

The New England journal of medicine 2016; (375(20)):1925-1936 doi:10.1056/NEJMoa1607303.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, et al.

Journal of bone oncology 2017; (7()):1-12 doi:10.1016/j.jbo.2017.03.001.

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

Saha P, Regan MM, Pagani O, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(27)):3113-3122 doi:10.1200/JCO.2016.72.0946.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Krop I, Ismaila N, Andre F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(24)):2838-2847 doi:10.1200/JCO.2017.74.0472.

Clinicopathologic predictors of lymph node metastasis in breast cancer patients according to molecular subtype.

Chas M, Boivin L, Arbion F, et al.

Journal of gynecology obstetrics and human reproduction 2018; (47(1)):9-15 doi:10.1016/j.jogoh.2017.10.008.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, et al.

The New England journal of medicine 2017; (377(19)):1836-1846 doi:10.1056/NEJMoa1701830.

Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.

Ahn S, Lee J, Cho MS, et al.

Archives of pathology & laboratory medicine 2018; (142(3)):364-368 doi:10.5858/arpa.2017-0014-OA.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, et al.

JAMA oncology 2018; (4(4)):545-553 doi:10.1001/jamaoncol.2017.5524.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1941-1948 doi:10.1200/JCO.2017.76.4258.

Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence.

Murata T, Jinno H, Takahashi M, et al.

The breast journal 2019; (25(1)):9-15 doi:10.1111/tbj.13033.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, et al.

The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.

Petrossian K, Kanaya N, Lo C, et al.

Oncotarget 2018; (9(45)):27736-27751 doi:10.18632/oncotarget.25552.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, et al.

JAMA 2018; (320(2)):167-176 doi:10.1001/jama.2018.8907.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Van Asten K, Slembrouck L, Olbrecht S, et al.

The oncologist 2019; (24(2)):165-171 doi:10.1634/theoncologist.2018-0176.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.

Geyer CE, Tang G, Mamounas EP, et al.

NPJ breast cancer 2018; (4()):37 doi:10.1038/s41523-018-0090-6.

Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.

Jayasekara H, MacInnis RJ, Chamberlain JA, et al.

International journal of cancer 2019; (145(12)):3207-3217 doi:10.1002/ijc.32214.

Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ.

Magnoni F, Massari G, Santomauro G, et al.

The British journal of surgery 2019; (106(4)):375-383 doi:10.1002/bjs.11079.

Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.

Baglia ML, Lin IH, Cartmel B, et al.

Cancer 2019; (125(13)):2262-2271 doi:10.1002/cncr.32051.

The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

Ramchand SK, Cheung YM, Yeo B, Grossmann M

The Journal of endocrinology 2019; (241(3)):R111-R124.

Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia.

Anand K, Niravath P

Current oncology reports 2019; (21(6)):51 doi:10.1007/s11912-019-0795-1.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(13)):3865-3872 doi:10.1158/1078-0432.CCR-19-0376.

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

André F, Ciruelos E, Rubovszky G, et al.

The New England journal of medicine 2019; (380(20)):1929-1940 doi:10.1056/NEJMoa1813904.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1956-1964 doi:10.1200/JCO.19.00945.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Henry NL, Somerfield MR, Abramson VG, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1965-1977 doi:10.1200/JCO.19.00948.

Prognostic Factors for Luminal B-like Breast Cancer.

Ding NH, Liu CF, Hu C, et al.

Current medical science 2019; (39(3)):396-402 doi:10.1007/s11596-019-2049-8.

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer.

Cheung YM, Ramchand SK, Yeo B, Grossmann M

Journal of the Endocrine Society 2019; (3(7)):1283-1301 doi:10.1210/js.2019-00096.

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.

Bartlett JMS, Sgroi DC, Treuner K, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2019; (30(11)):1776-1783 doi:10.1093/annonc/mdz289.

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

Allison KH, Hammond MEH, Dowsett M, et al.

Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.

Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.

Miyashita H, Satoi S, Kuno T, et al.

Breast cancer research and treatment 2020; (181(2)):279-289 doi:10.1007/s10549-020-05640-3.

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.

Jayasekera J, Sparano JA, Gray R, et al.

JNCI cancer spectrum 2019; (3(4)):pkz062 doi:10.1093/jncics/pkz062.

Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.

Bago-Horvath Z, Rudas M, Singer CF, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(21)):5682-5688 doi:10.1158/1078-0432.CCR-20-0673.

Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer.

Syed YY

Molecular diagnosis & therapy 2020; (24(5)):621-632 doi:10.1007/s40291-020-00482-7.

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

Conte B, Bruzzone M, Lambertini M, et al.

European journal of cancer (Oxford, England : 1990) 2020; (136()):43-51 doi:10.1016/j.ejca.2020.05.007.

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.

Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(28)):3273-3281 doi:10.1200/JCO.19.02427.

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Johnston SRD, Harbeck N, Hegg R, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(34)):3987-3998 doi:10.1200/JCO.20.02514.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Korde LA, Somerfield MR, Carey LA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis.

Boland MR, Al-Maksoud A, Ryan ÉJ, et al.

The British journal of surgery 2021; (108(1)):24-31 doi:10.1093/bjs/znaa048.

Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.

Schnell PM, Lustberg MB, Henry NL

JNCI cancer spectrum 2021; (5(2)) doi:10.1093/jncics/pkab018.

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

Burstein HJ, Somerfield MR, Barton DL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(35)):3959-3977 doi:10.1200/JCO.21.01392.

Omission of sentinel node biopsy for breast cancer: Historical context and future perspectives on a modern controversy.

Jatoi I, Kunkler IH

Cancer 2021; (127(23)):4376-4383 doi:10.1002/cncr.33960.

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.

Paakkola NM, Karakatsanis A, Mauri D, et al.

ESMO open 2021; (6(6)):100289 doi:10.1016/j.esmoop.2021.100289.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

Eisen A, Somerfield MR, Accordino MK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(7)):787-800 doi:10.1200/JCO.21.02647.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

The Lancet. Oncology 2022; (23(3)):382-392 doi:10.1016/S1470-2045(21)00758-0.

Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features.

Munkácsy G, Santarpia L, Győrffy B

Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020248.

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

Andre F, Ismaila N, Allison KH, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.

Blanchette P, Sivajohanathan D, Bartlett J, et al.

Current oncology (Toronto, Ont.) 2022; (29(4)):2599-2615 doi:10.3390/curroncol29040213.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard FC, Kaklamani VG, Neven P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(28)):3246-3256 doi:10.1200/JCO.22.00338.

Five decades of progress in surgical oncology: Breast.

Downs-Canner S, Cody HS

Journal of surgical oncology 2022; (126(5)):852-859 doi:10.1002/jso.27035.

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.

Vliek SB, Hilbers FS, Jager A, et al.

European journal of cancer (Oxford, England : 1990) 2022; (175()):169-179 doi:10.1016/j.ejca.2022.07.036.

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.

Vrselja A, Latifi A, Baber RJ, et al.

Lancet (London, England) 2022; (400(10364)):1704-1711 doi:10.1016/S0140-6736(22)01977-8.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Johnston SRD, Toi M, O'Shaughnessy J, et al.

The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.

Sirico M, Virga A, Conte B, et al.

Critical reviews in oncology/hematology 2023; (181()):103900 doi:10.1016/j.critrevonc.2022.103900.

The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.

Lashen AG, Toss MS, Mongan NP, et al.

Cancer 2023; (129(8)):1183-1194 doi:10.1002/cncr.34655.

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.

Kunkler IH, Williams LJ, Jack WJL, et al.

The New England journal of medicine 2023; (388(7)):585-594 doi:10.1056/NEJMoa2207586.

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.

Huppert LA, Gumusay O, Idossa D, Rugo HS

CA: a cancer journal for clinicians 2023; (73(5)):480-515 doi:10.3322/caac.21777.

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

Voorwerk L, Sanders J, Keusters MS, et al.

NPJ breast cancer 2023; (9(1)):39 doi:10.1038/s41523-023-00543-0.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Turner NC, Oliveira M, Howell SJ, et al.

The New England journal of medicine 2023; (388(22)):2058-2070 doi:10.1056/NEJMoa2214131.

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.

Slamon DJ, Fasching PA, Hurvitz S, et al.

Therapeutic advances in medical oncology 2023; (15()):17588359231178125 doi:10.1177/17588359231178125.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.

Wolff AC, Somerfield MR, Dowsett M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(22)):3867-3872 doi:10.1200/JCO.22.02864.

The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer.

Makhlouf S, Althobiti M, Toss M, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(10)):100284 doi:10.1016/j.modpat.2023.100284.

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7.

Prat A, Solovieff N, André F, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(4)):793-802 doi:10.1158/1078-0432.CCR-23-0561.

Ribociclib-induced liver injury: a case report.

Schaeffer S, Lutz C, Dobbie M, et al.

Frontiers in oncology 2023; (13()):1256783 doi:10.3389/fonc.2023.1256783.

LUMINA: Using molecular biomarkers to guide decision making for breast radiotherapy.

Whelan TJ, Fyles A, Parpia S, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2024; (190()):110074 doi:10.1016/j.radonc.2023.110074.

Ki-67 Testing in Breast Cancer: Assessing Variability With Scoring Methods and Specimen Types and the Potential Subsequent Impact on Therapy Eligibility.

Bocklage T, Cornea V, Hickey C, et al.

Applied immunohistochemistry & molecular morphology : AIMM 2024; (32(3)):119-124 doi:10.1097/PAI.0000000000001188.

Current and future advances in practice: aromatase inhibitor-induced arthralgia.

Kim S, Chen N, Reid P

Rheumatology advances in practice 2024; (8(2)):rkae024 doi:10.1093/rap/rkae024.

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.

Sirico M, Jacobs F, Molinelli C, et al.

Critical reviews in oncology/hematology 2024; (200()):104404 doi:10.1016/j.critrevonc.2024.104404.

Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.

Lin W, Zeng Y, Weng L, et al.

BMC pharmacology & toxicology 2024; (25(1)):47 doi:10.1186/s40360-024-00770-6.

Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.

Ascione L, Castellano G, Curigliano G, Zagami P

Current opinion in oncology 2024; (36(6)):465-473 doi:10.1097/CCO.0000000000001085.

Real-World Implications of the SOUND Trial.

Giannakou A, Kantor O, Park KU, et al.

Annals of surgical oncology 2024; (31(13)):8776-8785 doi:10.1245/s10434-024-16354-x.

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.

Tau S, Chamberlin MD, Yang H, et al.

Cancer research 2025; (85(6)):1145-1161 doi:10.1158/0008-5472.CAN-24-1204.

Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer.

Dean B

Journal of the advanced practitioner in oncology 2024; 1-8 doi:10.6004/jadpro.2024.15.8.11.

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

Cardoso F, O'Shaughnessy J, Liu Z, et al.

Nature medicine 2025; (31(2)):442-448 doi:10.1038/s41591-024-03415-7.

Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment.

Schumacher JR, Tucholka JL, Breuer CR, et al.

Annals of surgical oncology 2025; (32(5)):3252-3259 doi:10.1245/s10434-025-16959-w.

Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

Cooper K, Nalbant G, Essat M, et al.

Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Lammers SWM, Geurts SME, Hermans KEPE, et al.

ESMO open 2025; (10(2)):104154 doi:10.1016/j.esmoop.2025.104154.

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

Park KU, Somerfield MR, Anne N, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

Purification and biochemical characterization of mutant ligand binding domain of human estrogen receptor α protein.

Palaniappan M, Bohren KM

The Journal of steroid biochemistry and molecular biology 2025; (251()):106763 doi:10.1016/j.jsbmb.2025.106763.

Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer.

Marín-Liébana S, Llor P, Serrano-García L, et al.

Cancers 2025; (17(9)) doi:10.3390/cancers17091482.

Real-world chemotherapy use and survival outcomes in postmenopausal HR+/HER2-breast cancer with low genomic risk (RS ≤ 25): a multicenter cohort study from China.

Hong C, Wang D, Chen Y, et al.

Scientific reports 2026; (16(1)).

De-Escalation of Axillary Surgery: A Review of Choosing Wisely Guideline Evidence.

Grapes A, Young J, Takabe K

World journal of oncology 2026; (17(3)):277-291 doi:10.14740/wjon2710.

Omission of Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Expanding Evidence in Clinically Node-Negative and Neoadjuvant Therapy Responders.

Grapes A, Young J, Takabe K

World journal of oncology 2026; (17(3)):292-309 doi:10.14740/wjon2776.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Francis PA, Pagani O, Fleming GF, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2026; (37(10)):1367-1385 doi:10.1016/j.annonc.2026.05.704.

Association between endocrine therapy and survival outcomes in estrogen receptor-low breast cancer: a systematic review and meta-analysis.

Xia F, Hu X, Zhang L, et al.

The oncologist 2026; (31(7)) doi:10.1093/oncolo/oyag230.

Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer.

Dragoumis D, Kapetsis G, Louis K, et al.

Cancers 2026; (18(11)) doi:10.3390/cancers18111731.

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Kalinsky K, Barlow WE, Pathak HB, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2026; (37(9)):1220-1229 doi:10.1016/j.annonc.2026.05.697.

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Chen H, Wu S, Shan Y, et al.

Cancer medicine 2026; (15(8)):e72224 doi:10.1002/cam4.72224.